Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis

These data suggest that Q4W is an effective dosing regimen for most patients who achieved stable disease control as shown by clear/almost clear skin and no itch to mild itch over 4 consecutive weeks on the initial regimen of tralokinumab Q2W.